<DOC>
	<DOCNO>NCT01684423</DOCNO>
	<brief_summary>The purpose study find whether rivaroxaban safe use child long stay body . There also check bleed worsen blood clot .</brief_summary>
	<brief_title>Oral Rivaroxaban Children With Venous Thrombosis</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Children age 6 &lt; 18 year treat least 2 month , case catheterrelated thrombosis , least 6 week LMWH ( low molecular weight heparin ) , fondaparinux and/or VKA ( vitamin K antagonist ) document symptomatic asymptomatic venous thrombosis Hemoglobin , platelet , creatinine alanine aminotransferase ( ALT ) total bilirubin evaluate within 10 day prior randomization Informed consent provide , applicable , child assent provide Active bleed high risk bleed contraindicate anticoagulant therapy Symptomatic progression venous thrombosis precede anticoagulant treatment Planned invasive procedure , include lumbar puncture removal non peripherally place central line study treatment An estimate glomerular filtration rate ( eGFR ) &lt; 30 mL/min/1.73 m2 Hepatic disease associate coagulopathy lead clinically relevant bleeding risk ALT &gt; 5x upper level normal ( ULN ) total bilirubin &gt; 2x ULN direct bilirubin &gt; 20 % total Platelet count &lt; 50 x 10^9/L Hypertension define &gt; 95th age percentile Life expectancy &lt; 3 month Concomitant use strong inhibitor cytochrome P450 isoenzyme 3A4 ( CYP3A4 ) Pglycoprotein ( Pgp ) , i.e . human immunodeficiency virus protease inhibitor follow azole antimycotic agent : ketoconazole , itraconazole , voriconazole , posaconazole , use systemically Concomitant use strong inducer CYP3A4 , i.e . rifampicin , rifabutin , phenobarbital , phenytoin carbamazepine</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>